DACG VI
DACG VI. Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer
Sponsor study identifier
Secondary identifiers
OTHER · The Regional Ethics Committee for the Central Denmark Region
observational
80
1 country
3
Study Start
November 13, 2025
Actual (reported)Primary Completion
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of this observational study is to learn how radiotherapy for anal cancer affects the vaginal and sexual health of women after treatment. The study will also look at whether the radiation dose to the vagina is linked to the level of vaginal problems. The main questions this study aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 13, 2025
Actual (reported)December 9, 2025
Actual (reported)December 22, 2025
Actual (reported)September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prevalence of moderate to severe vaginal stenosis after radiotherapy for anal cancer
This outcome measures how many participants have moderate or severe narrowing of the vagina after treatment for anal cancer. Vaginal stenosis will be assessed during a gynaecological examination using a standard clinical grading system CTCAE v. 5.
Single assessment at study visit, 6 to 36 months after completion of chemoradiotherapy
Gynecological findings at examination after radiotherapy for anal cancer
Single assessment at study visit, 6 to 36 months after completion of chemoradiotherapy
Patient-reported sexual health and quality of life after radiotherapy for anal cance
Single assessment at study visit, 6 to 36 months after completion of chemoradiotherapy
Use of vaginal dilators, hormone treatment, and sexual counselling after radiotherapy
Single questionnaire assessment at study visit, 6 to 36 months after completion of chemoradiotherapy
Radiation dose to the vagina and its relation to vaginal stenosis
Retrospective analysis of radiotherapy plans after study inclusion
Patient satisfaction with guidance on gynecological and sexual side effects
Single telephone interview within 3 months after study inclusion
The study population includes adult women who have been treated with chemoradiotherapy for anal cancer in Denmark. Participants are recruited during routine follow-up visits at three oncology departments. All participants are between 6 and 36 months after treatment and are in cancer follow-up care
Department of Oncology Aarhus University Hospital (AUH)
Aarhus, 8200, Denmark
Department of Oncology, Herlev and Gentofte Hospital
Herlev, 2730, Denmark
First Submitted
December 9, 2025
First Posted
December 22, 2025
Study Start
November 13, 2025
Actual (reported)Primary Completion
September 1, 2026
Estimated (date passed)HPV Genotype Attribution and Disease Burden of Anal Cancer in China
Contact the study team to confirm eligibility.
Department of Oncology Vejle Hospital, University Hospital of Southern Denmark
Vejle, 7100, Denmark
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 22, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: